Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.31 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549941 | 1.00 | IRAK4 (0.34) | IRAK4MERTKKDM1ASLC6A4USP30 | |
| SCHEMBL14782788 | 0.80 | KDM1A (0.44) | KDM1ASLC6A4 | |
| SCHEMBL5549932 | 0.74 | USP30 (0.42) | USP30JAK2 | |
| SCHEMBL5549920 | 0.74 | USP30 (0.42) | USP30JAK2 | |
| SCHEMBL5543235 | 0.74 | USP30 (0.42) | USP30JAK2 | |
| SCHEMBL5545234 | 0.74 | USP30 (0.42) | USP30JAK2 | |
| SCHEMBL5545238 | 0.74 | USP30 (0.42) | USP30JAK2 | |
| SCHEMBL5543229 | 0.74 | USP30 (0.42) | USP30JAK2 | |
| SCHEMBL5545416 | 0.73 | CRBN (0.46) | — | |
| SCHEMBL3206535 | 0.73 | MAOB (0.41) | IRAK4MERTKKDM1ASLC6A4TRPC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | claimed |
| US-7230002-B2 | Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-06-12 | — | — | US | disclosed |
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | DPP4, DPP3, DPP7 | IRAK4 1478/4885MERTK 2987/4885KDM1A 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.